Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Upregulation of indoleamine 2,3-dioxygenase in hepatitis C virus infection.

Larrea E, Riezu-Boj JI, Gil-Guerrero L, Casares N, Aldabe R, Sarobe P, Civeira MP, Heeney JL, Rollier C, Verstrepen B, Wakita T, Borrás-Cuesta F, Lasarte JJ, Prieto J.

J Virol. 2007 Apr;81(7):3662-6. Epub 2007 Jan 17.

2.

Indolamine 2,3-dioxygenase expression by monocytes and dendritic cell populations in hepatitis C patients.

Schulz S, Landi A, Garg R, Wilson JA, van Drunen Littel-van den Hurk S.

Clin Exp Immunol. 2015 Jun;180(3):484-98. doi: 10.1111/cei.12586.

3.

Regulation of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA-synthetase by CTLA-4-Fc in human CD4+ T cells.

Boasso A, Herbeuval JP, Hardy AW, Winkler C, Shearer GM.

Blood. 2005 Feb 15;105(4):1574-81. Epub 2004 Oct 5.

4.

Upregulation of indoleamine 2,3-dioxygenase in hepatocyte during acute hepatitis caused by hepatitis B virus-specific cytotoxic T lymphocytes in vivo.

Iwamoto N, Ito H, Ando K, Ishikawa T, Hara A, Taguchi A, Saito K, Takemura M, Imawari M, Moriwaki H, Seishima M.

Liver Int. 2009 Feb;29(2):277-83. doi: 10.1111/j.1478-3231.2008.01748.x. Epub 2008 Apr 5.

PMID:
18397228
5.

Regulatory T-cell markers, indoleamine 2,3-dioxygenase, and virus levels in spleen and gut during progressive simian immunodeficiency virus infection.

Boasso A, Vaccari M, Hryniewicz A, Fuchs D, Nacsa J, Cecchinato V, Andersson J, Franchini G, Shearer GM, Chougnet C.

J Virol. 2007 Nov;81(21):11593-603. Epub 2007 Aug 22.

6.

Antiviral and Immunoregulatory Effects of Indoleamine-2,3-Dioxygenase in Hepatitis C Virus Infection.

Lepiller Q, Soulier E, Li Q, Lambotin M, Barths J, Fuchs D, Stoll-Keller F, Liang TJ, Barth H.

J Innate Immun. 2015;7(5):530-44. doi: 10.1159/000375161. Epub 2015 Mar 19.

7.

Association of enhanced activity of indoleamine 2,3-dioxygenase in dendritic cells with the induction of regulatory T cells in chronic hepatitis C infection.

Higashitani K, Kanto T, Kuroda S, Yoshio S, Matsubara T, Kakita N, Oze T, Miyazaki M, Sakakibara M, Hiramatsu N, Mita E, Imai Y, Kasahara A, Okuno A, Takikawa O, Hayashi N, Takehara T.

J Gastroenterol. 2013 May;48(5):660-70. doi: 10.1007/s00535-012-0667-z. Epub 2012 Sep 14.

PMID:
22976933
8.

Interferon-gamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin.

O'Connor JC, André C, Wang Y, Lawson MA, Szegedi SS, Lestage J, Castanon N, Kelley KW, Dantzer R.

J Neurosci. 2009 Apr 1;29(13):4200-9. doi: 10.1523/JNEUROSCI.5032-08.2009.

9.

Kynurenine production mediated by indoleamine 2,3-dioxygenase aggravates liver injury in HBV-specific CTL-induced fulminant hepatitis.

Ohtaki H, Ito H, Ando K, Ishikawa T, Hoshi M, Ando T, Takamatsu M, Hara A, Moriwaki H, Saito K, Seishima M.

Biochim Biophys Acta. 2014 Sep;1842(9):1464-71. doi: 10.1016/j.bbadis.2014.04.015. Epub 2014 Apr 24.

10.

Decreased indoleamine 2,3-dioxygenase expression in dendritic cells and role of indoleamine 2,3-dioxygenase-expressing dendritic cells in immune thrombocytopenia.

Xu SQ, Wang CY, Zhu XJ, Dong XY, Shi Y, Peng J, Qin P, Sun JZ, Guo C, Ni H, Hou M.

Ann Hematol. 2012 Oct;91(10):1623-31. doi: 10.1007/s00277-012-1451-0. Epub 2012 Apr 13.

PMID:
22526360
11.

Proapoptotic activity of indoleamine 2,3-dioxygenase expressed in renal tubular epithelial cells.

Mohib K, Guan Q, Diao H, Du C, Jevnikar AM.

Am J Physiol Renal Physiol. 2007 Sep;293(3):F801-12. Epub 2007 Jul 3.

12.

Indoleamine-2,3-dioxygenase as an effector and an indicator of protective immune responses in patients with acute hepatitis B.

Yoshio S, Sugiyama M, Shoji H, Mano Y, Mita E, Okamoto T, Matsuura Y, Okuno A, Takikawa O, Mizokami M, Kanto T.

Hepatology. 2016 Jan;63(1):83-94. doi: 10.1002/hep.28282. Epub 2015 Nov 23.

PMID:
26458241
13.

Uveal melanoma expression of indoleamine 2,3-deoxygenase: establishment of an immune privileged environment by tryptophan depletion.

Chen PW, Mellon JK, Mayhew E, Wang S, He YG, Hogan N, Niederkorn JY.

Exp Eye Res. 2007 Nov;85(5):617-25. Epub 2007 Jul 25.

14.

No augmentation of indoleamine 2,3-dioxygenase (IDO) activity through belatacept treatment in liver transplant recipients.

Bigenzahn S, Juergens B, Mahr B, Pratschke J, Koenigsrainer A, Becker T, Fuchs D, Brandacher G, Kainz A, Muehlbacher F, Wekerle T.

Clin Exp Immunol. 2018 May;192(2):233-241. doi: 10.1111/cei.13093. Epub 2018 Feb 2.

15.

CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques.

Hryniewicz A, Boasso A, Edghill-Smith Y, Vaccari M, Fuchs D, Venzon D, Nacsa J, Betts MR, Tsai WP, Heraud JM, Beer B, Blanset D, Chougnet C, Lowy I, Shearer GM, Franchini G.

Blood. 2006 Dec 1;108(12):3834-42. Epub 2006 Aug 8. Erratum in: Blood. 2009 Oct 1;114(14):3132.

16.

Astrocyte indoleamine 2,3-dioxygenase is induced by the TLR3 ligand poly(I:C): mechanism of induction and role in antiviral response.

Suh HS, Zhao ML, Rivieccio M, Choi S, Connolly E, Zhao Y, Takikawa O, Brosnan CF, Lee SC.

J Virol. 2007 Sep;81(18):9838-50. Epub 2007 Jul 11.

17.

Flavivirus infection induces indoleamine 2,3-dioxygenase in human monocyte-derived macrophages via tumor necrosis factor and NF-κB.

Yeung AW, Wu W, Freewan M, Stocker R, King NJ, Thomas SR.

J Leukoc Biol. 2012 Apr;91(4):657-66. doi: 10.1189/jlb.1011532. Epub 2012 Feb 1.

PMID:
22301793
18.

Upregulated expression of indoleamine 2, 3-dioxygenase in CHO cells induces apoptosis of competent T cells and increases proportion of Treg cells.

Sun J, Yu J, Li H, Yang L, Wei F, Yu W, Liu J, Ren X.

J Exp Clin Cancer Res. 2011 Sep 14;30:82. doi: 10.1186/1756-9966-30-82.

19.

Constitutive expression of IDO by dendritic cells of mesenteric lymph nodes: functional involvement of the CTLA-4/B7 and CCL22/CCR4 interactions.

Onodera T, Jang MH, Guo Z, Yamasaki M, Hirata T, Bai Z, Tsuji NM, Nagakubo D, Yoshie O, Sakaguchi S, Takikawa O, Miyasaka M.

J Immunol. 2009 Nov 1;183(9):5608-14. doi: 10.4049/jimmunol.0804116.

20.

Targeting indoleamine 2,3-dioxygenase (IDO) to counteract tumour-induced immune dysfunction: from biochemistry to clinical development.

Rutella S, Bonanno G, De Cristofaro R.

Endocr Metab Immune Disord Drug Targets. 2009 Jun;9(2):151-77. Review.

PMID:
19519465

Supplemental Content

Support Center